Compound · clinical trials

Leucovorin clinical trials

Also listed in trial records as Levoleucovorin, Wellcovorin, Fusilev, Khapzory, CL-307, Elvorine, Isovorin, Levofolene, Levorin, Folinate, Calcium Levofolinate Hydrateb

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 117 trials in our USA, China, Canada, Spain, France, Italy, Japan, Australia, Germany, South Korea, Taiwan, Israel, UK, Mexico, Netherlands, Belgium, Brazil, Poland, Czechia, Turkey, Switzerland, Austria, Norway, Ireland, Denmark, Portugal, Sweden, Egypt, Singapore and India registers that name Leucovorin as an intervention. Synced 8 Nov 2026

117Current trials

65Recruiting now

71Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 8 Nov 2026 · Editorial standards

At a glance

Leucovorin is named as an intervention in 117 current clinical trials in our USA, China, Canada, Spain, France, Italy, Japan, Australia, Germany, South Korea, Taiwan, Israel, UK, Mexico, Netherlands, Belgium, Brazil, Poland, Czechia, Turkey, Switzerland, Austria, Norway, Ireland, Denmark, Portugal, Sweden, Egypt, Singapore and India registers. 65 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute (NCI) (9). The most-studied condition is Colorectal Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.

Where Leucovorin is approved

All regulators →

Of the three regulators tracked here, the first to approve Leucovorin was the US, on 20 Jun 1952. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)

20 Jun 1952

Leucovorin Calcium

NDA008107 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

27 Apr 1994

Leucovorin Calcium

Notice of Compliance 5376

First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Leucovorin patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Leucovorin, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

US FDA Orange Book Vykoura

1 listed patent; the last listed expires 23 Dec 2044 (US 12564592).

See the Orange Book listing for NDA 220406

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Leucovorin

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$12.3m

163,087 prescriptions in 2025 · Leucovorin Calcium, Leucovorin Calcium, leucovorin calcium

+51% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Leucovorin works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

AIDSPhase 3
Langerhans cell histiocytosisPhase 3
Biliary tract cancerPhase 3
Breast cancerPhase 3
Carcinoma of esophagusPhase 3
Carcinoma of the ampulla of vaterPhase 3
CholangiocarcinomaPhase 3
Colon adenocarcinomaPhase 3
Colorectal cancerPhase 3
Colorectal carcinomaPhase 3

82 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1679, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6690, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Leucovorin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Leucovorin

ChEMBL: CHEMBL1679
DrugBank: DB00650
PubChem CID: 135403648
CAS number: 58-05-9
FDA UNII: Q573I9DVLP
Wikidata: Q45435667
Wikipedia: Folinic acid

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting6556%
Not yet open87%
Active, closed4337%
By invitation11%

Trials by phase

Phase 24438%
Phase 33026%
Phase 11815%
Phase 1/21715%
Phase 2/354%
Not applicable22%
Phase 411%

Clinical trials of Leucovorin

117 trials

Study	Phase	Status	Lead sponsor	Registers
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials NCT05203172 · Solid Tumors	Phase 4	Recruiting	Pfizer	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Australia, Israel
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC NCT03303495 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms	Phase 3	Recruiting	Sun Yat-sen University	China
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy NCT03959085 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer NCT04215731 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Yanhong Deng	China
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) NCT04447352 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Krankenhaus Nordwest	Germany
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer NCT05253651 · Colorectal Neoplasms	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Norway, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer NCT06205485 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Canadian Cancer Trials Group	Canada, Mexico
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. NCT06733038 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. NCT06897644 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Advanced or Metastatic	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Brazil, Mexico, Japan, South Korea
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer NCT07228832 · Metastatic Colorectal Cancer (CRC)	Phase 3	Recruiting	Summit Therapeutics	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Canada, Mexico, Japan, Egypt
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial NCT07271355 · ClinicalTrials.gov ↗ · Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum	Phase 3	Recruiting	City of Hope Medical Center	Egypt
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer NCT07409272 · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Poland, Brazil, Japan, South Korea, Taiwan
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer NCT07472868 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Phase 3	Recruiting	J. W. A. Burger	Netherlands
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc	UK, USA, Italy, Netherlands, Austria
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) NCT07775287 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Genmab	USA
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations NCT06279130 · ClinicalTrials.gov ↗ · Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors	Phase 2/3	Recruiting	The Netherlands Cancer Institute	Netherlands
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. NCT03401294 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	University of Saskatchewan	Canada
Pan Tumor Rollover Study NCT03899155 · Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) NCT05472259 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	Belgian Group of Digestive Oncology	Belgium
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico, Israel, Egypt
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer NCT05571644 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients NCT05727163 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Sun Yat-sen University	China
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 · Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Poland, Canada, Japan, South Korea, Taiwan, Singapore, Australia
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer NCT06253611 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	GERCOR - Multidisciplinary Oncology Cooperative Group	France
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer NCT06820463 · Metastatic Colorectal Cancer	Phase 2	Recruiting	AbbVie	UK, USA, France, Spain, Italy, Austria, Czechia, Canada, Brazil, Japan, Taiwan, Australia, Israel
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448 · Colorectal Cancer	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	USA, France, Spain, Italy, Canada, Japan
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma NCT07015242 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Recruiting	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	USA, Germany, France
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma NCT07069712 · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Italy, Poland, Turkey, Canada, Japan, Taiwan
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) NCT07183865 · ClinicalTrials.gov ↗ · Locally Recurrent Rectal Cancer	Phase 2	Recruiting	Fudan University	China
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas NCT07290985 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	American Association for Cancer Research	Canada
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 · Solid Tumors	Phase 2	Recruiting	Mirati Therapeutics Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Singapore, Australia, Israel
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) NCT07432295 · Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 2	Recruiting	I-Mab Biopharma US Limited	USA, China, Japan, Egypt
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer NCT07474727 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Multitude Therapeutics Inc	China
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
A Placebo-controlled Trial of Folinic Acid in Children With ASD NCT07642661 · ClinicalTrials.gov ↗ · Autism Spectrum Disorder	Phase 2	Recruiting	Prof. Adi Aran	Israel
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC NCT07733180 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	BeOne Medicines	Japan
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland, Canada
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer NCT07797816 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. NCT04689347 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Italy
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer NCT05379595 · Advanced or Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Janssen Research & Development, LLC	USA, China, Germany, Spain, Italy, Belgium, Canada, South Korea, Taiwan
FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 · ClinicalTrials.gov ↗ · Cancer, Colorectal Cancer, Solid Tumor	Phase 1/2	Recruiting	Parabilis Medicines, Inc	USA, Australia
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation NCT06385925 · Malignant Neoplasm	Phase 1/2	Recruiting	Tyligand Pharmaceuticals (Suzhou) Limited	USA, China
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Czechia, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer NCT07444541 · Pancreatic Cancer	Phase 1/2	Recruiting	Anova Innovation Limited	USA
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation NCT07678593 · Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation	Phase 1/2	Recruiting	Genfleet Therapeutics (Shanghai) Inc	China, Australia
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer NCT07805551 · ClinicalTrials.gov ↗ · CRC, Colorectal Cancer	Phase 1/2	Recruiting	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd	China
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas NCT03715933 · Ewing Sarcoma, Colorectal Adenocarcinoma	Phase 1	Recruiting	Inhibrx Biosciences, Inc	UK, USA, France, Spain, Italy, Netherlands
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China, Spain, Italy, Denmark, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA, China, France, Spain, Italy, Japan, South Korea
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China, France, Spain, Japan, South Korea, Israel
A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558 · Advanced Solid Tumors	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China, France, Spain, Netherlands, Sweden, Canada, Japan, Israel
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer NCT06825624 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer NCT07024615 · Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors NCT07277270 · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA, Spain, Canada, South Korea, Australia
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805 · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer	Phase 1	Recruiting	Pfizer	USA, France, Spain
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays NCT07283939 · ClinicalTrials.gov ↗ · Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile	Not applicable	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy NCT07803783 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 3	Not yet open	MediLink Therapeutics (Suzhou) Co., Ltd	China
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment NCT06662877 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Second Line Treatment, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment NCT07028424 · ClinicalTrials.gov ↗ · PDAC - Pancreatic Ductal Adenocarcinoma	Phase 2	Not yet open	GERCOR - Multidisciplinary Oncology Cooperative Group	France
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial NCT07625930 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Not yet open	McGill University Health Centre/Research Institute of the McGill University Health Centre	Canada
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment NCT06370754 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation NCT06409637 · ClinicalTrials.gov ↗ · Liver Cancer, Liver Transplant	Phase 1/2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer NCT07314385 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Metastatic, Liver Metastasis	Phase 1	Not yet open	National Taiwan University Hospital	Taiwan
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer NCT07441369 · ClinicalTrials.gov ↗ · Liver Metastases From Colorectal Cancer (mCRC)	Phase 2	By invitation	Fudan University	China
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia NCT02003222 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia NCT02101853 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia, Israel
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma NCT02112916 · ClinicalTrials.gov ↗ · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL) NCT02572141 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 3	Active, closed	Sun Yat-sen University	China
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair NCT02912559 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Germany, Mexico, Israel
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study NCT02997228 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia	Phase 3	Active, closed	Children's Oncology Group	Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia NCT03914625 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) NCT04008030 · Metastatic Colorectal Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Austria, Czechia, Norway, Turkey, Canada, Brazil, Japan, Australia
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer NCT04607421 · Neoplasms	Phase 3	Active, closed	Pfizer	UK, USA, India, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) NCT06625320 · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Revolution Medicines, Inc	USA, Germany, France, Spain, Italy, Japan
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma NCT01924819 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	Australasian Gastro-Intestinal Trials Group	Germany, France, Spain, Belgium, Czechia, Canada, Australia, Israel
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery NCT04068103 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8	Phase 2/3	Active, closed	NRG Oncology	Canada, Mexico
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer NCT05141721 · Colorectal Neoplasms	Phase 2/3	Active, closed	Seattle Project Corporation	USA
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia NCT02981628 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia	Phase 2	Active, closed	Children's Oncology Group	Israel
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness NCT03421288 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, Switzerland
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM NCT03493048 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2	Active, closed	Sun Yat-sen University	China
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer NCT03505320 · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc	USA, France, Italy, Japan, South Korea, Taiwan
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer NCT03764553 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Active, closed	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread NCT04233866 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT04390399 · Pancreatic Cancer	Phase 2	Active, closed	ImmunityBio, Inc	USA
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA, Mexico, Japan
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer NCT05026905 · ClinicalTrials.gov ↗ · Phase II, Open-label, Parallel 2-arm, Multi-center	Phase 2	Active, closed	National Health Research Institutes, Taiwan	China, Taiwan
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer NCT05382442 · Metastatic Colorectal Cancer	Phase 2	Active, closed	Akeso	USA, China
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) NCT05564403 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer NCT05843188 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Active, closed	University Health Network, Toronto	Canada
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc	USA, Germany, France, Spain
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer NCT06094140 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	Australasian Gastro-Intestinal Trials Group	Australia
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma NCT06628310 · Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma	Phase 2	Active, closed	AbbVie	UK, USA, China, Germany, Spain, Belgium, Canada, Japan, Taiwan, Israel
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma NCT07257575 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III	Phase 2	Active, closed	Guangdong Provincial People's Hospital	China
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I NCT02553460 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 1/2	Active, closed	St. Jude Children's Research Hospital	Canada
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma NCT03817320 · ClinicalTrials.gov ↗ · ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood	Phase 1/2	Active, closed	Therapeutic Advances in Childhood Leukemia Consortium	Australia
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8	Phase 1/2	Active, closed	Flemming Forsberg	Norway
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. NCT05355701 · Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer	Phase 1	Active, closed	Pfizer	USA, Canada, Israel
First in Human Study of AZD9592 in Solid Tumors NCT05647122 · Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms	Phase 1	Active, closed	AstraZeneca	USA, China, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Australia
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 · ClinicalTrials.gov ↗ · Advanced Cancer, Advanced Malignancies, Bladder Cancer	Phase 1	Active, closed	Arcus Biosciences, Inc	USA, Taiwan, Australia
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA, France, Spain, Italy, Netherlands, Belgium, South Korea
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer NCT06547385 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors NCT06586515 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	Ireland, USA, China, Germany, France, Spain, Italy, Canada, Japan
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA, Germany, France, Spain, Italy, Belgium, Japan, Taiwan
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia NCT04562558 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia, Stage I Gestational Trophoblastic Tumor	Not applicable	Active, closed	xiang yang	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Leucovorin in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Leucovorin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases 2025-524215-36-00 · Neoplasms	Phase 2	Authorised	Unicancer	France

Leucovorin across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Supply shortages

No entry for Leucovorin in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Recent approvals

Leucovorin CalciumFDA · 12 Nov 2025 · Generic (ANDA) · Gland

EMA approvals tracker FDA approvals tracker

Conditions studied with Leucovorin

154 conditions

Colorectal Cancer12 Gastric Cancer8 Pancreatic Ductal Adenocarcinoma7 Pancreatic Cancer7 Metastatic Colorectal Cancer6 Colorectal Neoplasms6 Biliary Tract Cancer5 Gastroesophageal Junction Adenocarcinoma5Gastroesophageal Adenocarcinoma4Advanced Solid Tumors4B Acute Lymphoblastic Leukemia4Esophageal Adenocarcinoma3

All 154 conditions

Condition (as registered)	Trials
Colorectal Cancer	12
Gastric Cancer	8
Pancreatic Ductal Adenocarcinoma	7
Pancreatic Cancer	7
Metastatic Colorectal Cancer	6
Colorectal Neoplasms	6
Biliary Tract Cancer	5
Gastroesophageal Junction Adenocarcinoma	5
Gastroesophageal Adenocarcinoma	4
Advanced Solid Tumors	4
B Acute Lymphoblastic Leukemia	4
Esophageal Adenocarcinoma	3
PDAC - Pancreatic Ductal Adenocarcinoma	3
Esophageal Cancer	3
Solid Tumor	3
Acute Lymphoblastic Leukemia	3
Cancer	2
Non-small Cell Lung Cancer	2
Solid Tumors	2
Neoplasms	2
Metastatic Colorectal Cancer (CRC)	2
PDAC	2
Metastatic Pancreatic Cancer	2
Metastatic Pancreatic Adenocarcinoma	2
Advanced Cancer	2
Esophageal Squamous Cell Carcinoma	2
Gastric Adenocarcinoma	2
Metastatic Colorectal Adenocarcinoma	2
Rectal Cancer	2
Colon Adenocarcinoma	2
Mixed Phenotype Acute Leukemia	2
Metastatic Pancreatic Ductal Adenocarcinoma	2
Stage II Pancreatic Cancer AJCC v8	2
Recurrent B Acute Lymphoblastic Leukemia	2
B Lymphoblastic Lymphoma	2
Stage IV Pancreatic Cancer AJCC v8	2
Metastatic Gastric Adenocarcinoma	1
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma	1
Gastroesophageal Junction Cancer	1
Pancreatic Cancer Metastatic	1
Carcinoma, Non-Small-Cell Lung	1
Stomach Neoplasms	1
Ewing Sarcoma	1
Colorectal Adenocarcinoma	1
Locally Advanced Solid Tumor	1
Metastatic Cancer	1
Lymphoma	1
Advanced Unresectable Gastric Adenocarcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
Advanced Solid Tumours	1
Carcinoma Non-small Cell Lung	1
Head and Neck Neoplasms	1
Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Pancreatic Adenocarcinoma	1
Advanced Solid Tumor	1
Advanced Malignancies	1
Bladder Cancer	1
Cervical Cancer	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Gastroesophageal Junction	1
Esophageal Neoplasms	1
Pharmacokinetics of Zolbetuximab	1
Gastro-esophageal Junction (GEJ) Cancer	1
Pharmacokinetics of Oxaliplatin	1
Colorectal Carcinoma	1
GEJ Adenocarcinoma	1
HER2-positive Breast Cancer	1
HER2-positive Gastric Cancer	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Melanoma	1
Non-Small-Cell Lung Cancer	1
Thyroid Cancer	1
Glioma	1
Malignant Neoplasm	1
Advanced Breast Cancer	1
Metastatic Breast Cancer (HR+/ HER2-)	1
Advanced or Metastatic Colorectal Cancer	1
Malignant Neoplam	1
Neoplasm Metastasis	1
Intestinal Neoplasms	1
Gastrointestinal Neoplasms	1
Colorectal Cancer Metastatic	1
Colon Cancer	1
Liver Metastases From Colorectal Cancer (mCRC)	1
Advanced Solid Tumors Cancer	1
RAS Mutation	1
Liver Metastases	1
Phase II, Open-label, Parallel 2-arm, Multi-center	1
Solid Cancer	1
Gestational Trophoblastic Tumor	1
Gestational Trophoblastic Neoplasia	1
Stage I Gestational Trophoblastic Tumor	1
Stage II Gestational Trophoblastic Tumor	1
Locally Recurrent Rectal Cancer	1
Liver Cancer	1
Liver Transplant	1
Second Line Treatment	1
Chemotherapy	1
Tyrosine Kinase Inhibitor	1
Gastric Cancer Stage III	1
GC/GEJC	1
CRC, Colorectal Cancer	1
Pancreatic Ductal Adenocarcinoma (PDAC)	1
DNA Repair Disorder	1
Lynch Syndrome	1
Stage III Colon Cancer AJCC v8	1
T Acute Lymphoblastic Leukemia	1
Pancreatic Adenocarcinoma Advanced or Metastatic	1
Locally Advanced Rectal Carcinoma	1
Resectable MMR-deficient Solid Tumors	1
Resectable MMR-proficient Solid Tumors	1
Locally Advanced Pancreatic Ductal Adenocarcinoma	1
Stage IIA Pancreatic Cancer AJCC v8	1
Stage IIA Colon Cancer AJCC v8	1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1
Central Nervous System Leukemia	1
Down Syndrome	1
Adult T Acute Lymphoblastic Leukemia	1
Ann Arbor Stage II Adult Lymphoblastic Lymphoma	1
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	1
Ann Arbor Stage III Adult Lymphoblastic Lymphoma	1
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma	1
Stage III Pancreatic Cancer AJCC v8	1
Ampulla of Vater Carcinoma	1
Appendix Carcinoma	1
Carcinoma of Unknown Primary With Gastrointestinal Profile	1
Colon Carcinoma	1
Advanced Biliary Tract Carcinoma	1
Advanced Gallbladder Carcinoma	1
Advanced Intrahepatic Cholangiocarcinoma	1
Recurrent Biliary Tract Carcinoma	1
Stage IV Colorectal Cancer AJCC v7	1
Advanced Malignant Solid Neoplasm	1
Anatomic Stage III Breast Cancer AJCC v8	1
Anatomic Stage IV Breast Cancer AJCC v8	1
Locally Advanced Malignant Solid Neoplasm	1
Advanced Esophageal Squamous Cell Carcinoma	1
Metastatic Esophageal Squamous Cell Carcinoma	1
Pancreatic Adenocarcinoma Metastatic	1
Liver Metastasis	1
ALL, Childhood	1
Lymphoblastic Lymphoma, Childhood	1
Lymphoblastic Leukemia, Acute, Childhood	1
Recurrent B Lymphoblastic Lymphoma	1
Refractory B Acute Lymphoblastic Leukemia	1
Refractory B Lymphoblastic Lymphoma	1
Autism Spectrum Disorder	1
Metastatic Appendix Carcinoma	1
Metastatic Colorectal Carcinoma	1
Metastatic Malignant Neoplasm in the Peritoneum	1
Stage IV Appendix Carcinoma AJCC v8	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	51	35
Clinical trials in China	50	31
Clinical trials in Canada	38	22
Clinical trials in Spain	31	21
Clinical trials in France	30	19
Clinical trials in Italy	30	21
Clinical trials in Japan	29	19
Clinical trials in Australia	26	15
Clinical trials in Germany	23	12
Clinical trials in South Korea	20	16
Clinical trials in Taiwan	20	12
Clinical trials in Israel	20	10
Clinical trials in UK	19	16
Clinical trials in Mexico	18	8
Clinical trials in Netherlands	15	10
Clinical trials in Belgium	14	7
Clinical trials in Brazil	12	10
Clinical trials in Poland	11	10
Clinical trials in Czechia	10	6
Clinical trials in Turkey	9	8
Clinical trials in Switzerland	9	7
Clinical trials in Austria	8	6
Clinical trials in Norway	7	4
Clinical trials in Ireland	4	2
Clinical trials in Denmark	4	2
Clinical trials in Portugal	4	4
Clinical trials in Sweden	4	2
Clinical trials in Egypt	4	4
Clinical trials in Singapore	3	3
Clinical trials in India	2	1
EU register (CTIS)	1	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Leucovorin trials

How many clinical trials are testing Leucovorin?

117 current trials in our USA, China, Canada, Spain, France, Italy, Japan, Australia, Germany, South Korea, Taiwan, Israel, UK, Mexico, Netherlands, Belgium, Brazil, Poland, Czechia, Turkey, Switzerland, Austria, Norway, Ireland, Denmark, Portugal, Sweden, Egypt, Singapore and India registers name Leucovorin (also registered as CL-307) as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.

Are Leucovorin trials recruiting patients?

Yes. 65 of the 117 trials are recruiting: 35 with sites in USA, 31 with sites in China, 22 with sites in Canada, 21 with sites in Spain, 19 with sites in France, 21 with sites in Italy, 19 with sites in Japan, 15 with sites in Australia, 12 with sites in Germany, 16 with sites in South Korea, 12 with sites in Taiwan, 10 with sites in Israel, 16 with sites in UK, 8 with sites in Mexico, 10 with sites in Netherlands, 7 with sites in Belgium, 10 with sites in Brazil, 10 with sites in Poland, 6 with sites in Czechia, 8 with sites in Turkey, 7 with sites in Switzerland, 6 with sites in Austria, 4 with sites in Norway, 2 with sites in Ireland, 2 with sites in Denmark, 4 with sites in Portugal, 2 with sites in Sweden, 4 with sites in Egypt, 3 with sites in Singapore and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Leucovorin clinical trials?

National Cancer Institute (NCI) (9), Merck Sharp & Dohme LLC (6), Sun Yat-sen University (6) and Astellas Pharma Global Development, Inc (5), among 71 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Leucovorin clinical trials in Ireland?

Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is there a Leucovorin shortage?

Not in the lists we track: Leucovorin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Leucovorin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Leucovorin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Leucovorin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.